Welcome to our dedicated page for Peraso SEC filings (Ticker: PRSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Peraso Inc. (NASDAQ: PRSO) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, drawn from the U.S. Securities and Exchange Commission’s EDGAR system. Peraso is a fabless semiconductor company focused on 60 GHz unlicensed and 5G mmWave wireless technology, and its filings offer detailed insight into its capital structure, governance, financing activities and financial performance.
Investors can review Form 10‑K annual reports and Form 10‑Q quarterly reports to understand how Peraso describes its business, risk factors and results of operations, including its focus on mmWave chipsets, antenna modules, software and IP. These core filings typically include segment information, discussion of fixed wireless access and other applications, and management’s analysis of revenue, expenses and non-GAAP metrics.
Peraso’s frequent Form 8‑K current reports document material events such as earnings releases, strategic review updates, prospectus supplements for at-the-market equity offerings, changes in outstanding securities, and governance matters. For example, 8‑K filings describe the company’s ongoing strategic review and interactions with Mobix Labs, amendments to its Amended and Restated 2019 Stock Incentive Plan, the appointment of director Cees Links, and notices related to regaining compliance with Nasdaq’s minimum bid price requirement.
This page also surfaces registration statements and prospectus supplements that outline Peraso’s at-the-market offering program, as well as disclosures on outstanding warrants, stock options, restricted stock units and the Series A special voting preferred stock. Where available, Form 4 insider transaction reports can be used to track equity transactions by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify items such as changes in capital structure, non-GAAP reconciliations, board and committee changes, and updates on strategic alternatives. Real-time updates ensure that new Peraso filings appear promptly, giving investors an efficient way to follow the company’s regulatory history and ongoing reporting.
Peraso Inc. (PRSO) announced a confidentiality agreement with Mobix Labs on October 30, 2025, as part of its ongoing review of strategic alternatives. The pact includes customary terms, notably a mutual 12-month standstill and non-solicitation provisions.
This is an administrative step that allows both companies to exchange information under agreed boundaries while Peraso evaluates potential paths. No financial terms or transactions were disclosed in connection with this notice.
Peraso Inc. disclosed that it filed a new prospectus supplement to increase the capacity of its at-the-market equity program with Ladenburg Thalmann. The supplement raises the maximum amount of common stock that can be issued under the existing Sales Agreement to up to an aggregate of $1,750,000 of shares.
This new limit is separate from the $2,686,953 in shares that have already been sold under the agreement. The shares are being offered under Peraso’s effective Form S-3 shelf registration statement and related base prospectus, as further detailed in prior and current prospectus supplements.
PRSO is updating its at-the-market stock offering program, allowing it to sell additional common shares with an aggregate offering price of up to $1,750,000 through Ladenburg Thalmann under an existing sales agreement. This fits within Form S-3 rules that cap primary offerings at one-third of its public float.
The company also outlines an ongoing unsolicited approach from Mobix Labs, which has moved from an initial stock-based proposal to a revised all-cash indication of $1.30 per share. Mobix has discussed a potential hostile exchange offer but, as of October 9, 2025, has not commenced any tender or exchange offer. The board is conducting a strategic review with financial and legal advisors and states there is no assurance any transaction with Mobix or others will occur.
Peraso Inc. filed an S-3 shelf registration to register shares for resale by certain selling stockholders and to register shares issuable upon exercise of outstanding warrants and options. The filing shows up to 1,019,047 shares issuable on exercise of the Warrants, and assumes October 7, 2025 as a full-exercise date producing 8,809,757 total shares and Exchangeable Shares outstanding after exercise. Several broker-dealer placement agent warrants and inducement warrants are listed (including placement agent warrants issued to Ladenburg Thalmann and affiliates). The capitalization disclosures list multiple warrant series and option pools, including 3,974,520 shares issuable upon exercise of Series A warrants at $2.25, 1,293,650 Series C warrants at $1.61, and other series with specified exercise prices. The prospectus also lists selling stockholders with specific pre- and post-offering beneficial ownership percentages and a range of permitted distribution methods. Filing exhibits and fees are enumerated and officers signed the registration.
Mobix Labs, Inc. has filed a Schedule TO-C describing pre-commencement communications for a potential tender offer to acquire the issued and outstanding shares of Peraso, Inc. common stock. This filing makes clear that no tender offer has begun yet and that any future offer would be detailed in formal tender offer materials filed on Schedule TO, along with Peraso’s response on Schedule 14D-9.
The communication emphasizes that Peraso security holders should carefully review any future tender offer documents and recommendation statement before deciding whether to tender their shares. It also includes extensive forward-looking statement disclosures, outlining uncertainties such as Peraso’s willingness to engage, regulatory approvals, financing conditions, market volatility, and integration risks if a transaction is ultimately pursued.
Peraso Inc. disclosed the detailed schedule of outstanding equity instruments that could convert into common stock, listing option, warrant, restricted stock unit, and reserve quantities. Key items include 837,380 shares held in abeyance, 1,333,794 shares from outstanding stock options (weighted average exercise price $3.38), a 213,438 share reserve under its 2019 Stock Incentive Plan, and multiple tranches of warrants across 2022–2025 with exercise prices ranging from $1.25 to $40.00. The filing shows 952,380 Series E warrants dated September 12, 2025 at an exercise price of $1.25 and 66,667 placement agent warrants at $1.475. Aggregating the listed items yields approximately 11.5 million shares of common stock potentially issuable upon exercise or conversion of the instruments disclosed.
Peraso Inc. (PRSO) filed a Form D reporting a completed Regulation D offering totaling $1,288,809. The filing states the offering involved equity and related warrants: 952,380 shares issuable upon exercise of Series E warrants at $1.25 per share and 66,667 shares issuable upon exercise of placement agent warrants at $1.475 per share.
The offering was conducted under Rule 506(b) with a reported first sale date of 2025-09-11 and shows a single investor participated. Ladenburg Thalmann & Co. Inc. is listed as the broker-dealer, sales commissions are reported as $244,477 (estimate), and the issuer indicates $0 of the proceeds were used to pay executive officers, directors or promoters.
Peraso Inc. reported that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement. The company received a notification letter from Nasdaq’s Listing Qualifications Department on September 19, 2025, confirming that it again meets the minimum bid price standard under Nasdaq Listing Rule 5550(a)(2). A press release dated September 22, 2025 providing further detail is included as an exhibit to this report.
Peraso Inc. reported that it is continuing its strategic review and has received a revised unsolicited proposal from Mobix Labs, Inc. to acquire the company using both cash and stock consideration in an undetermined amount. Peraso has invited Mobix Labs to join a limited exploratory call, structured so that Peraso does not share material non-public information and does not operate under a confidentiality agreement. The call, if held on these or other mutually acceptable terms, would help Peraso better understand Mobix Labs’ updated proposal and intentions, but no transaction has been agreed.
Peraso Inc. received a notice from Nasdaq that its common stock no longer meets the minimum bid price requirement of $1 per share. This determination was based on the stock’s closing bid price over 30 consecutive business days ending September 4, 2025.
The company has 180 calendar days, until March 4, 2026, to regain compliance. To do so, its stock must close at or above $1 per share for at least ten consecutive business days during this period. If it fails, Peraso may qualify for an additional 180-day extension if it meets other Nasdaq Capital Market standards and notifies Nasdaq of plans to cure the deficiency, potentially through a reverse stock split.
The notice does not cause immediate delisting, but Peraso’s common stock could be removed from the Nasdaq Capital Market if it cannot restore compliance. The company states it is monitoring its share price and evaluating its options.